vemurafenib (Zelboraf, PLX4032)

From Aaushi
Jump to navigation Jump to search

Indications

* for use in combination with cobimetinib

Adverse effects

Laboratory

Mechanism of action

  • BRAF inhibitor
    • designed to selectively target & inhibit a mutated form of BRAF

More general terms

References

  1. New Drug Applications http://www.roche.com/med-cor-2011-05-11-e.pdf
  2. FDA NEWS RELEASE: Aug. 17, 2011 FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer
  3. 3.0 3.1 Guedj M et al. Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib. JAMA Opthalmol 2014 Aug 14 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25125216 <Internet> http://archopht.jamanetwork.com/article.aspx?articleid=1895298
  4. ClinicalTrials.gov Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma. https://clinicaltrials.gov/study/NCT03224767

Database